Insights

Mounjaro

Earnest Analytics
  • Healthcare
  • Pharmacy

Mounjaro GLP1 leader in 2024
  • Healthcare
  • Pharmacy

Significant number of ex-Mounjaro patients switch to Ozempic 
  • Healthcare
  • Pharmacy

Barriers to GLP1 access drive higher telehealth use by patients living with obesity 
  • Healthcare
  • Pharmacy

GLP-1 Series Part 4: End of Mounjaro’s bridge program drove improved gross-to-net
  • Healthcare
  • Pharmacy

GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
  • Healthcare
  • Pharmacy

GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
arrow-downarrow-leftarrow-rightcaret-down-menucaret-downcarrot-rightcheckclosefacebook-squarefilterhamburgerinstagram-squarelinkedin-squaremobile-parent-indicatorpauseplayprintertwitter-square